MA50087A - Vésicules extracellulaires provenant de prevotella - Google Patents

Vésicules extracellulaires provenant de prevotella

Info

Publication number
MA50087A
MA50087A MA050087A MA50087A MA50087A MA 50087 A MA50087 A MA 50087A MA 050087 A MA050087 A MA 050087A MA 50087 A MA50087 A MA 50087A MA 50087 A MA50087 A MA 50087A
Authority
MA
Morocco
Prior art keywords
prevotella
extracellular vesicles
vesicles
extracellular
Prior art date
Application number
MA050087A
Other languages
English (en)
Inventor
Baundauna Bose
Will Caffry
Sofia M R Carlton
Christopher J H Davitt
Brian Goodman
Hank Wu
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of MA50087A publication Critical patent/MA50087A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
MA050087A 2017-09-08 2018-09-10 Vésicules extracellulaires provenant de prevotella MA50087A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556020P 2017-09-08 2017-09-08
US201862632859P 2018-02-20 2018-02-20
US201862668556P 2018-05-08 2018-05-08

Publications (1)

Publication Number Publication Date
MA50087A true MA50087A (fr) 2020-07-15

Family

ID=63832483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050087A MA50087A (fr) 2017-09-08 2018-09-10 Vésicules extracellulaires provenant de prevotella

Country Status (12)

Country Link
US (2) US20190240263A1 (fr)
EP (1) EP3679057A1 (fr)
JP (2) JP2020533291A (fr)
KR (1) KR20200053532A (fr)
CN (1) CN111526881A (fr)
AU (1) AU2018330323A1 (fr)
BR (1) BR112020004347A2 (fr)
CA (1) CA3075270A1 (fr)
MA (1) MA50087A (fr)
MX (1) MX2020002660A (fr)
TW (1) TWI840334B (fr)
WO (1) WO2019051381A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126831A1 (fr) 2015-02-03 2016-08-11 Mayo Foundation For Medical Education And Research Méthodes et matériels d'évaluation et de traitement de l'arthrite
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
EP3678693A1 (fr) 2017-09-08 2020-07-15 Evelo Biosciences, Inc. Vésicules extracellulaires (ev) bactériennes
US11433139B2 (en) 2018-03-16 2022-09-06 Zoetis Services Llc Peptide vaccines against interleukin-31
ES3037451T3 (en) * 2018-11-30 2025-10-02 Ospedale San Raffaele Srl Prevotella melaninogenica strain for use against cancer or diabetes
CN113727722A (zh) * 2019-02-22 2021-11-30 伊夫罗生物科学公司 细菌膜制剂
AU2020278746A1 (en) * 2019-05-21 2021-12-16 Evelo Biosciences, Inc. Methods and compositions for anaerobic bacterial fermentation
CA3143025A1 (fr) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Vesicules extracellulaires microbiennes traitees
CN114340732A (zh) * 2019-06-17 2022-04-12 梅约医学教育与研究基金会 普氏菌属制剂以及治疗慢性阻塞性肺部疾病(copd)和其他肺部疾病
CN114245742A (zh) * 2019-06-21 2022-03-25 伊夫罗生物科学公司 使用普雷沃菌属治疗th2介导的病症的组合物和方法
EP4007807A1 (fr) * 2019-08-02 2022-06-08 Evelo Biosciences, Inc. Procédés et compositions pour la culture de bactéries dépendant de l'hémoglobine
KR20220044315A (ko) * 2019-08-05 2022-04-07 에벨로 바이오사이언시즈, 인크. 프레보텔라 히스티콜라를 사용한 건선 및 아토피성 피부염을 치료하기 위한 조성물 및 방법
WO2021108502A1 (fr) 2019-11-27 2021-06-03 Evelo Biosciences, Inc. Procédés et compositions pour la culture de bactéries dépendantes de l'hémoglobine
JP2023522018A (ja) * 2020-04-17 2023-05-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 改善された崩壊プロファイルを有する固形剤形
MX2023000945A (es) * 2020-07-21 2023-03-15 Evelo Biosciences Inc 55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias.
WO2022051494A1 (fr) * 2020-09-03 2022-03-10 Evelo Biosciences, Inc. Compositions et méthodes de résolution d'inflammation
MX2023003089A (es) * 2020-09-18 2023-05-09 Evelo Biosciences Inc Formas farmaceuticas solidas de bacterias.
WO2022061141A1 (fr) * 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Compositions et méthodes de traitement d'une inflammation à l'aide de prevotella histicola
TW202227110A (zh) * 2020-09-21 2022-07-16 美商艾弗洛生物科技股份有限公司 用棲組織普雷沃菌調節免疫反應之組成物及方法
WO2022092783A1 (fr) * 2020-10-27 2022-05-05 재단법인 아산사회복지재단 Application de la souche prevotella stercorea pour la prévention ou le traitement du cancer
TW202233213A (zh) 2020-10-29 2022-09-01 美商艾弗洛生物科技股份有限公司 包含螺旋藻組分之組成物
EP4267154A1 (fr) * 2020-12-22 2023-11-01 Evelo Biosciences, Inc. Compositions comprenant de l'hémoglobine animale
CN112611877B (zh) * 2020-12-31 2022-09-16 四川大学华西医院 一款利用angptl4预测急性呼吸窘迫综合征患病及预后的试剂盒
JP2024505207A (ja) * 2021-01-26 2024-02-05 エヴェロ バイオサイエンシズ，インコーポレーテッド プレボテラ（Ｐｒｅｖｏｔｅｌｌａ）細胞外小胞調製物
US20240148797A1 (en) * 2021-02-26 2024-05-09 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (fr) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions et procédés de traitement d'une inflammation à l'aide de prevotella histicola
WO2022251166A2 (fr) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Compositions bactériennes comprenant de l'hémoglobine de soja
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统
KR20230024502A (ko) 2021-08-12 2023-02-21 (주)프로스테믹스 miRNA를 포함하는 세포외 소포 및 이의 용도
CN113509494A (zh) * 2021-09-06 2021-10-19 南京医科大学 普氏菌在制备治疗胆汁淤积性疾病的药物中的应用
WO2023107537A1 (fr) 2021-12-07 2023-06-15 Evelo Biosciences, Inc. Compositions d'anticorps et procédés d'utilisation avec des vésicules extracellulaires et microbes
WO2023146843A1 (fr) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Compositions de vésicules extracellulaires et méthodes d'utilisation
WO2023200837A1 (fr) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions et méthodes de traitement d'une inflammation à l'aide de prevotella histicola
US20250235433A1 (en) * 2022-04-19 2025-07-24 Cedars-Sinai Medical Center Methods of treating and diagnosing fatty liver disease
EP4518888A1 (fr) * 2022-05-06 2025-03-12 The Regents of the University of Colorado, a body corporate Immunobiotiques pour prévenir une pneumonie bactérienne et leurs procédés d'utilisation
WO2023239728A1 (fr) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions et méthodes de traitement d'une inflammation à l'aide de vésicules extracellulaires de prevotella histicola
WO2025076308A1 (fr) * 2023-10-06 2025-04-10 University Of Florida Research Foundation, Incorporated Compositions et méthodes pour analyser l'effet du microbiote sur la conformation des protéines hôtes et pour traiter des maladies neurodégénératives
CN117481145B (zh) * 2023-10-26 2024-05-10 湖北省生物农药工程研究中心 几丁质结合蛋白BvCBP及其复配物在制备植物害螨杀螨剂中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322784A (en) * 1991-06-05 1994-06-21 The Board Of Trustees Of The University Of Illinois, Urbana-Champaign, Illinois Method and materials for introducing DNA into Prevotella ruminicola
HUP0204546A3 (en) * 2000-03-01 2003-10-28 Nestle Sa Carbohydrate formulation for enhancement of immune response
WO2011027971A2 (fr) * 2009-09-01 2011-03-10 주식회사이언메딕스 Vésicules extracellulaires dérivées de la flore intestinale, et procédé de recherche d'un modèle de maladie, d'un vaccin et d'un médicament candidat, et de diagnostic utilisant ce dernier
WO2011053653A2 (fr) * 2009-10-30 2011-05-05 Mayo Foundation For Medical Education And Research Préparations à base de prevotella histicola et traitement d'états auto-immuns
US9408880B2 (en) * 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
JP5635690B2 (ja) * 2010-07-01 2014-12-03 ポステック アカデミー‐インダストリー ファウンデーション 細菌由来マイクロベシクルを用いた癌治療及び癌診断方法
TR201815566T4 (tr) * 2013-06-03 2018-11-21 Proprev Ab Prevotella'dan en az bir bakteri suşu kullanarak obezite, metabolik sendrom, tip 2 diyabet, kardiyovasküler hastalıklar, demans, alzheimer hastalığı ve enflamatuvar bağırsak hastalığının tedavisi.
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
US10722543B2 (en) * 2016-01-28 2020-07-28 Oxyrase, Inc. Methods for inhibiting tumor growth using anaerobe microorganisms

Also Published As

Publication number Publication date
CA3075270A1 (fr) 2019-03-14
JP2020533291A (ja) 2020-11-19
JP2023153808A (ja) 2023-10-18
EP3679057A1 (fr) 2020-07-15
MX2020002660A (es) 2020-07-22
AU2018330323A1 (en) 2020-03-19
US20190240263A1 (en) 2019-08-08
US20230405058A1 (en) 2023-12-21
BR112020004347A2 (pt) 2020-09-08
TWI840334B (zh) 2024-05-01
WO2019051381A1 (fr) 2019-03-14
CN111526881A (zh) 2020-08-11
KR20200053532A (ko) 2020-05-18
TW201920652A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
MA50087A (fr) Vésicules extracellulaires provenant de prevotella
IL277344A (en) Extracellular vesicles containing agonist-STING
MA50086A (fr) Vésicules extracellulaires (ev) bactériennes
EP3718983A4 (fr) Pare-brise
MA49549A (fr) Auto-injecteur
EP3602422A4 (fr) Apprentissage-machine de protection de la vie privée
EP3690389A4 (fr) Jauge de contrainte
EP3602439A4 (fr) Techniques de livraison supervisée
IL263727A (en) Extracellular vesicles with enhanced potency
EP3604005A4 (fr) Pare-brise
EP3852770A4 (fr) Vésicules extracellulaires modifiées en surface
EP3521427A4 (fr) Co-récepteur de récepteur odorant
UA32259S (uk) Розприскувач
EP3689999A4 (fr) Pulvérisateur
EP3580180C0 (fr) Système de dispersion de saumure
EP3898218C0 (fr) Produit en papier mousseline
IL280851A (en) Targeted extracellular vesicles
EP3429558C0 (fr) Polymersomes de fumarate
EP3554717C0 (fr) Appareil de pulvérisation
EP3733623A4 (fr) Pare-brise
DK3642475T3 (da) Hvirvelgenerator
DK3395738T3 (da) Dispenser
EP3577882C0 (fr) Visibilité de réseau
EP3621875A4 (fr) Véhicule aérien
EP3438473A4 (fr) Structure de raccord